Allergic rhinitis - the actual problem of the XXI century
- Authors: Dyneva M.E.1, Kurbacheva O.M.1
-
Affiliations:
- National Research Center - Institute of Immunology
- Issue: Vol 21, No 3 (2019)
- Pages: 65-68
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/96901
- DOI: https://doi.org/10.26442/20751753.2019.3.190268
- ID: 96901
Cite item
Full Text
Abstract
Allergic rhinitis (AR) is one of the most common chronic diseases of the upper respiratory tract throughout the world. Despite advances in understanding the mechanisms of allergic inflammation, the symptoms of AR in most cases are not completely controlled by modern methods of treatment. AR is a precursor and a predisposing factor for the development of other respiratory diseases, one of which is bronchial asthma. Therefore, it is important to diagnose AR in time and select the most effective and modern drugs that will not only help control the course of AR, but also improve the quality of life of patients. Intranasal glucocorticosteroids are recommended as first-line therapy for patients with varying severity of AR. The experience of using intranasal fluticasone propionate in Russia and abroad testifies to the effectiveness of this drug in the treatment of various forms of AR, both as mono-therapy and in combination with antihistamines and decongestants.
Full Text
##article.viewOnOriginalSite##About the authors
Miramgul E. Dyneva
National Research Center - Institute of Immunology
Email: amanturliva.miramgul@mail.ru
Graduate Student Moscow, Russia
Oksana M. Kurbacheva
National Research Center - Institute of ImmunologyD. Sci. (Med.), Full. Prof. Moscow, Russia
References
- Katelaris C.H, Lee B.W., Potter P.C et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exper Allergy 2011; 42: 186-207. doi: 10.1111/j.1365-2222.2011.03891.x
- Cong Li, Shen Y, Wang J et al. Increased Expression of IL-1R8 and a Possible immunomodulatory role of its ligand IL-37 in allergic rhinitis patients. Int Immunopharmacol 2018; 60 (1): 152-9. doi: 10.1016/j.intimp.2018.04.002
- Курбачева О.М., Польнер С.А., Смирнов Д.С. Аллергический Ринит. Мед. совет. 2015; 3: 84-91.
- Курбачева О.М. Аллерген-специфическая иммунотерапия. Рос. аллергологический журн. 2004; 2: 32-8.
- Павлова К.С. Новые вoзможности терапии аллергического ринита. Атмосфера. Пульмонология и аллергология. 2009; 3: 34-8.
- Чичкова Н. Бронхиальная астма и полипозный риносинусит : особенности клинического течения и тактика ведения больных. Астма и аллергия. 2015; 1: 19-22. [Chichkova N. Bronkhial'naia astma i polipoznyi rinosinusit: osobennosti klinicheskogo techeniia i 7. Allergies in America: A landmark survey of nasal allergy sufferers. Executive summary. Available online at http://www.worldallergy.org/ UserFiles/file/Allergies% 20in%20America%20(AIA)%20-%20Adult%20Executive%20Summary.pdf
- Greiwe J.C, Bernstein J.A. Combination Therapy in Allergic Rhinitis: What Works and What Does Not Work. Am J Rhinol Allergy 2016; 30 (6): 391-6. doi: 10.2500/ajra.2016.30.4391
- Derendorf H, Meltzer E.O. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292-300. doi: 10.1111/j.1398-9995.2008.01750.x
- Dykewicz M.S, Hamilos D.L. Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125 (Suppl.): 103-S115.
- Russell M.J, Pharm D, Dolen W.K. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther, Elsevier HS J 2017; 39 (12): 1-10. doi: 10.1016/j.clinthera.2017.10.006
- Wheatley L.M, Togias A. Clinical practice. Allergic rhinitis. New Engl J Med 2015; 372 (5): 456-63.
- Ludger K, Annette S, Sven B. Current therapeutical strategies for allergic rhinitis. Current Therapeutical Strategies for Allergic Rhinitis. Exp Opin Pharmacother 2018; 1-7. doi: 10.1080/14656566.2018.1543401
- Егорова О.А. Интраназальный глюкокортикостероид флутиказона пропионат (Назарел) в лечении аллергического ринита. Атмосфера. Пульмонология и аллергология. 2010; 1: 40-4. [Egorova O.A. Intranazal'nyi gliukokortikosteroid flutikazona propionat (Nazarel) v lechenii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2010; 1: 40-4 (in Russian).]
- Canonica G.W, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (Suppl. 85): 17-25. doi: 10.1111/j.1398-9995.2007.01549.x
- Dalal A.A, Stanford R, Henry H et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008; 101 (1): 23-9. doi: 10.1016/S1081-1206(10)60830-7
- Muganurmath C.S, Curry A.L, Schindzielorz A.H. Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria. Adv Ther 2018; 35 (2): 173-90. doi: 10.1007/s12325-018-0665-5
- Ratner P.H, van Bavel J.H, Martin B.G et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47: 118-25.
- Vaidyanathan S, Williamson P, Clearie K et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182: 19-24.
- Косякова Н.И., Лягина А.А., Андреева Л.А. и др. Влияние назального спрея флутиказона на показатели местного иммунитета у пациентов с аллергическим ринитом. Педиатрич. фармакология. 2006; 1: 72-4
Supplementary files
